Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy

被引:6
|
作者
Liu, Guoxiong [1 ]
Yin, Yinghao [2 ]
Zhang, Lei [3 ]
He, Dalin [1 ]
Yang, Lin [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[2] Cent South Univ, Dept Urol, Xiangya Hosp 3, Changsha, Hunan, Peoples R China
[3] Air Force Mil Med Univ, Dept Urol, Xijing Hosp, Xian, Shaanxi, Peoples R China
关键词
Dapoxetine; Sertraline; Premature ejaculation; Selective serotonin re-uptake inhibitors; INTERNATIONAL SOCIETY; DEFINITION; IMPACT; BLIND; MEN;
D O I
10.1016/j.esxm.2021.100473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Before dapoxetine was approved for the treatment of lifelong premature ejaculation (LPE) in China, daily dosing with off-label sertraline was common. Aim: To investigate the efficacy of dapoxetine in the treatment of patients with LPE as an alternative to sertraline therapy. Methods: This prospective study included LPE patients who previously attempted treatment with sertraline and who agree to receive dapoxetine therapy in our hospital from January 2020 to March 2021. Patients who received any PE therapy in the two months prior to the dapoxetine therapy were excluded. All patients received dapoxetine 30 mg (taken 1-3 hours before sexual intercourse) for 12 weeks, and they were not taking sertraline during the trial. Main Outcome Measure: Data on their intravaginal ejaculatory latency time and premature ejaculation profile were recorded before and after the dapoxetine treatment. Clinical Global Impression of Change scores and data on Treatment-Emergent adverse events were collected after treatment. Results: A total of 144 patients with LPE completed this study; including 64 patients who reported that previous sertraline treatment was satisfactory (group A) and 80 patients for whom previous sertraline therapy was unsatisfactory in treating PE (group B). Both groups experienced significantly increased intravaginal ejaculatory latency time. Dapoxetine therapy was reported satisfactory by 67.5% of patients with LPE in whom sertraline therapy unsatisfactory according to their Clinical Global Impression of Change score, which was not different from those who reported this result in group A (62.5%). Similar outcomes were also reported for premature ejaculation profile and treatment-emergent adverse events. Conclusion: : Although both dapoxetine and sertraline are selective serotonin re-uptake inhibitors, dapoxetine therapy is satisfactory in 67.5% of patients with LPE in whom sertraline treatment unsatisfactory, and the effect of dapoxetine was independent of the effect of sertraline. Copyright (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study
    Park, Hyun Jun
    Park, Nam Cheol
    Kim, Tae Nam
    Baek, Seung Ryong
    Lee, Kyung Min
    Choe, Sangmin
    SEXUAL MEDICINE, 2017, 5 (02): : E99 - E105
  • [42] Acceptance of and Discontinuation Rate from Paroxetine Treatment in Patients with Lifelong Premature Ejaculation
    Salonia, Andrea
    Rocchini, Lorenzo
    Sacca', Antonino
    Pellucchi, Federico
    Ferrari, Matteo
    Del Carro, Ubaldo
    Ribotto, Paolo
    Gallina, Andrea
    Zanni, Giuseppe
    Deho', Federico
    Rigatti, Patrizio
    Montorsi, Francesco
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 (10) : 2868 - 2877
  • [43] The Sympathetic Skin Response Located in the Penis as a Predictor of the Response to Sertraline Treatment in Patients with Primary Premature Ejaculation
    Xia, Jiadong
    Chen, Taowei
    Chen, Jie
    Han, Youfeng
    Xu, Zhipeng
    Zhou, Liuhua
    Chen, Yun
    Dai, Yutian
    JOURNAL OF SEXUAL MEDICINE, 2014, 11 (11) : 2801 - 2808
  • [44] A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation
    Kate Hutchinson
    Kelly Cruickshank
    Kevan Wylie
    Drug Safety, 2012, 35 : 359 - 372
  • [45] A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation
    Hutchinson, Kate
    Cruickshank, Kelly
    Wylie, Kevan
    DRUG SAFETY, 2012, 35 (05) : 359 - 372
  • [46] The effect of plasma melatonin levels in the treatment of lifelong premature ejaculation with selective serotonin reuptake inhibitors
    Kalkanli, Arif
    Gezmis, Cem Tugrul
    Fikri, Onur
    Cilesiz, Nusret Can
    Ozkan, Arif
    Eroglu, Ali
    Aydin, Memduh
    ANDROLOGIA, 2020, 52 (11)
  • [47] Relevance of seminal plasma nitric oxide levels and the efficacy of SSRI treatment on lifelong premature ejaculation
    Kirecci, S. L.
    Simsek, A.
    Yuksel, A.
    Gurdal, H.
    Gurbuz, Z. G.
    Usanmaz, S.
    ANDROLOGIA, 2014, 46 (10) : 1169 - 1175
  • [48] Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation
    Koyuncu, H.
    Serefoglu, E. C.
    Ozdemir, A. T.
    Hellstrom, W. J.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2012, 24 (05) : 171 - 173
  • [49] Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
    McCarty, E. J.
    Dinsmore, W. W.
    CORE EVIDENCE, 2012, 7 : 1 - 14
  • [50] Vital function of DRD4 in dapoxetine medicated premature ejaculation treatment
    Gao, Pan
    Liu, Xi
    Zhu, Tianle
    Gao, Rui
    Gao, Jingjing
    Zhang, Yao
    Jiang, Hui
    Huang, Houbao
    Zhang, Xiansheng
    ANDROLOGY, 2023, 11 (06) : 1175 - 1187